Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 178 of 5804
-
Could a third drug boost melanoma immunotherapy?
Disease control OngoingThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread fr…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New immune drug aims to keep lung cancer away after surgery
Disease control OngoingThis is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New stroke clot removal technique could boost recovery rates
Disease control CompletedMechanical thrombectomy (TM) is now validated through 4 randomized controlled trials of high scientific level as the reference treatment of cerebral infarction associated with proximal cerebral occlusion (MR CLEAN, ESCAPE 2014, 2015). These studies have shown for the first time a…
Phase: NA • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can an oral chemo pill boost immunotherapy's power against lung cancer?
Disease control TerminatedThe purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cance…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug cocktails aim to tackle tough myeloma
Disease control Recruiting nowThis study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). Th…
Phase: PHASE1, PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Keytruda plus radiation shows promise against lung cancer
Disease control CompletedThis randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation therapy) and to see how well they work in treating patien…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to wipe out hidden leukemia cells before they return
Disease control CompletedThis phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Personalized vaccine plus chemo cocktail aims to outsmart advanced ovarian cancer
Disease control TerminatedThis study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail …
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise against CLL
Disease control OngoingThis phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (ref…
Phase: PHASE1, PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a second round of pertuzumab help fight advanced breast cancer?
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC
-
New CLL drug acalabrutinib takes on ibrutinib in Head-to-Head trial
Disease control OngoingThis study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
Phase: PHASE3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could adding carboplatin to chemo keep triple-negative breast cancer away?
Disease control OngoingThis randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclopho…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New triple therapy targets hard-to-treat breast cancers
Disease control OngoingStudy combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
Phase: PHASE1, PHASE2 • Sponsor: Priyanka Sharma • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill shows promise for lung cancer patients with Hard-to-Treat mutation
Disease control CompletedA Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug cocktail shows promise in slowing EGFR lung cancer
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating ep…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Brain cancer vaccine shows promise in early trial
Disease control OngoingThis phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug shows promise for Hard-to-Treat bladder cancer
Disease control OngoingThe purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Lung cancer drug crizotinib tested as Post-Surgery shield
Disease control OngoingThis randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Surgery vs. pills: which keeps diabetes away longer?
Disease control Recruiting nowBariatric surgery procedures induce weight loss through restriction and/or malabsorption. The mechanisms underlying type 2 diabetes remission and others metabolic improvements after Roux-en-Y Gastric Bypass (RYGB), sleeve gastrectomy (SG) or biliopancreatic diversion with duodena…
Phase: NA • Sponsor: Laval University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New antibody combo aims to tackle Hard-to-Treat multiple myeloma
Disease control CompletedThis phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC